Core Viewpoint - TianKang Biological plans to acquire 51% of Qiangdu Livestock for 1.275 billion yuan, aiming for absolute control and flexible long-term development, with Qiangdu becoming a subsidiary post-acquisition [1] Group 1: Acquisition Details - The acquisition will bind the interests of the original controlling shareholder and includes a profit commitment of at least 837 million yuan over three years [1] - Qiangdu Livestock has a strong profitability record, with 1.36 million pigs expected to be sold in 2024 and over 1.5 million in 2025, maintaining profitability even during low price periods [1] Group 2: Future Projections - From 2026 to 2028, Qiangdu Livestock is projected to reach sales of 1.5 million, 1.58 million, and 1.61 million pigs respectively, with TianKang's total pig sales expected to exceed 3.2 million in 2025 [2] - Post-acquisition, TianKang's total pig sales could surpass 4 million, aiming for a target of 5 million, potentially moving from the 20th to the top 10 in national rankings [2] Group 3: Strategic Benefits - The acquisition aligns with national policies and enhances TianKang's competitive strength by integrating Qiangdu's established breeding base and technical team [3] - The merger will leverage TianKang's resources in feed research, animal vaccines, and breeding, while benefiting from Qiangdu's scale and reputation, facilitating a collaborative upgrade in operations [3] - The consolidation is expected to significantly boost TianKang's revenue and profit levels, supporting its strategic development in the pig farming industry [3]

Group 1: Acquisition Overview - TianKang Bio is acquiring 51% of Xinjiang Qiangdu Animal Husbandry Technology Co., Ltd., which retains 49% ownership, ensuring long-term interests are aligned [2] - Qiangdu has approximately 70,000 sows and is projected to produce 1.36 million pigs in 2024 and around 1.5 million in 2025 [1] - The acquisition is valued at 3.511 billion CNY, with the final agreed value set at 3.5 billion CNY, leading to an actual payment of 1.275 billion CNY after accounting for 1 billion CNY in unpaid profits [2] Group 2: Financial Structure and Performance - Qiangdu has maintained profitability for six consecutive years, even during the lowest pig prices in 2021 and 2023 [2] - The acquisition includes a performance commitment of at least 837 million CNY from 2025 to 2027, with a compensation cap of 534 million CNY if targets are not met [2] - The 1 billion CNY payable dividends will be distributed over five years, linked to annual performance, calculated at 70% of the annual profit [2] Group 3: Strategic Implications - The acquisition aligns with national policies to reduce breeding sows and does not involve new capacity or projects, facilitating rapid integration into the southern Xinjiang market [3] - By incorporating Qiangdu, TianKang Bio aims to significantly enhance its revenue and profit levels, supporting its "cluster-style" development strategy in the pig farming industry [3] - The deal is designed to optimize cash flow and reduce initial capital outlay by 510 million CNY, improving the cost-effectiveness of the acquisition [2]